Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:52:26.997Z.
Calculation as of: 2026-10-06T16:52:26.997Z.
Quote observation: 2026-10-06T16:38:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Satellos Bioscience Inc.
Market Cap
$10.34M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.34M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.32M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.31M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.61M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.96M | N/A |
| Lifeward Ltd. (LFWD)vs › | $9.92M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.11M | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
